Interleukin-6-dependent growth in a newly established plasmablastic lymphoma cell line and its therapeutic targets

Sohtaro Mine1,2, Tsunekazu Hishima3, Akihiko Suganuma4, Hitomi Fukumoto1, Yuko Sato3, Michiyo Kataoka2, Tsuyoshi Sekizuka5, Makoto Kuroda5, Tadaki Suzuki1, Hideki Hasegawa1, Masashi Fukayama2 & Harutaka Katano1

Plasmablastic lymphoma (PBL) is a rare, highly aggressive subtype of non-Hodgkin lymphoma with plasma-cell differentiation occurring typically in immune-suppressed patients such as those with AIDS. This study reports the establishment and characterization of a new cell line, PBL-1, derived from a patient with AIDS-associated PBL. Morphological assessment of PBL-1 indicated plasma-cell differentiation with a CD20(−)CD38(+)CD138(+) immunophenotype and IgH/c-myc translocation. The cell line harbours Epstein-Barr virus, but a 52.7-kbp length defect was identified in its genome, resulting in no expression of viral microRNAs encoded in the BamHI-A Rightward Transcript region. Importantly, supplementation of culture medium with >5 ng/mL of interleukin-6 (IL-6) was required for PBL-1 growth. Starvation of IL-6 or addition of tocilizumab, an inhibitory antibody for the IL-6 receptor, induced apoptosis of PBL-1. Transduction of IL-6 into PBL-1 by lentivirus vector induced autologous growth without IL-6 supplementation of culture medium. These data indicate the IL-6 dependency of PBL-1 for proliferation and survival. mTOR inhibitors induced cell death effectively, suggesting mTOR in the IL-6 signalling pathway is a potential therapeutic target for PBL. This established PBL cell line will be a useful tool to further understand the pathophysiology of PBL and aid the future development of PBL treatment.

Plasmablastic lymphoma (PBL) is a rare distinct clinicopathological entity of large B-cell malignant lymphoma, occurring typically in HIV-1 infected or other immunodeficient patients and is generally associated with Epstein–Barr virus (EBV) infection1. The incidence of PBL has been estimated as 2–8% of all cases of AIDS-related lymphomas2–4. Histologically, PBL cells have a large, round-to-irregular nucleus with a prominent nucleoli and perinuclear halo, as well as a variable amount of cytoplasm that is deeply basophilic. PBL cells do not express an immunophenotype typical for B-cell (surface and cytoplasmic immunoglobulin, CD19, CD20, CD79a) or T-cell (CD3, CD4, CD8) markers. Instead, several markers of lymphocyte activation (CD30, CD38, CD70, human leukocyte antigen DR) and plasma-cell differentiation (CD138, Blimp-1) are usually detected.

EBV has been detected in 66–74% of PBL cases5–6, suggesting it might play an important role in the tumorigenesis of PBL. EBV is a member of the oncogenic human gamma-herpesvirus family, and has been detected in Hodgkin lymphoma, Burkitt lymphoma, nasopharyngeal carcinoma, post-transplantation lymphoproliferative disorder, and gastric cancer. Approximately 40% of AIDS-related lymphoma cases are positive for EBV7. In PBL cases, EBV has been detected as Latency 1, expressing EBV-encoded small RNAs (EBERs) and EBV-encoded nuclear antigen 1 (EBNA-1). Although integration of EBV in the host chromosome was observed in several cell lines established from EBV-associated lymphoma with persistent infection8–11, there has been no report of an EBV integrated case of PBL.

1Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan. 2Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 3Department of Pathology, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan. 4Department of Infectious Diseases, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan. 5Pathogen Genomic Center, National Institute of Infectious Diseases, Tokyo, Japan. Correspondence and requests for materials should be addressed to H.K. (email: katano@nih.go.jp)
The prognosis of PBL is very poor, and a standard therapy for PBL has not been established\(^{1,14}\). Currently, a combination of antiretroviral therapy\(^{15,16}\) with a CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)-like regimen or more aggressive regimen including CODOX-M/IVAC (cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate alternating with ifosfamide, etoposide, and high-dose cytarabine), dose-adjusted EPOCH (infusional etoposide, vincristine and doxorubicin with bolus cyclophosphamide and prednisone), or HyperCVAD (hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and cytarabine) are considered first-line therapies\(^{1,17,18}\). Recently, cases treated with chemotherapy in combination with bortezomib, a proteasome inhibitor, have been reported\(^ {19-24}\).

Immortalized cell lines are useful tools to investigate disease pathogenesis and to evaluate the effects of therapeutic agents. To the best of our knowledge, there has been no report describing a well-characterized PBL cell line established from typical PBL cases. In this study, we established a PBL cell line from a case of AIDS-associated PBL, and demonstrated its interleukin 6 (IL-6)-dependent growth. In addition, the treatment effect of therapeutic agents was investigated.

## Results

### Establishment of a PBL cell line

At the beginning of the primary culture of tumour cells from the patient ascites, cells grew in RPMI 1640 culture medium supplemented with 10% patient ascites, 10% foetal bovine serum (FBS), 10 ng/mL insulin, and 10 ng/mL of transferrin at 37 °C with 5% CO\(_2\). After several passages, autologous ascites cells grew in RPMI 1640 culture medium supplemented with 10% patient ascites, 10% foetal bovine serum revealed that EBV in PBL-1 was genotype 1 (Supplementary Figure 3b). Reactivation of EBV was investigated by Cp and Wp promoters were not active in PBL-1 (Supplementary Figure 3c). EBV genotype-specific PCR analysis but no reads of miR-BART in 2,112,810 reads, while human miRNA were detected abundantly (Supplementary Figure 3c). EBV infection in PBL-1.

RT-PCR revealed that PBL-1 was positive for EBER-1 and EBNA-1 mRNA but negative for EBNA-2, latent membrane protein 1 (LMP-1), LMP-2A, and LMP-2B mRNA, indicating that the EBV genome of PBL-1 (numbering is based on strain M81, GenBank accession no. KF373730), indicating that EBV infection in PBL-1.

RT-PCR revealed that PBL-1 were positive for CD38, CD138, CD45RA, Blimp-1, MDM2, MyD88, gp80 (IL-6Ra), and gp130 (IL-6Rb) (Supplementary Figure 4). Flow cytometry and immunofluorescence analysis revealed that PBL-1 were positive for CD38, CD138, CD45RA, Blimp-1, MDM2, MyD88, gp80 (IL-6Ra), and gp130 (IL-6Rb) and negative for Kaposi’s sarcoma-associated herpesvirus (KSHV) and HIV-1 (Supplementary Figure 3a). The multivirus real-time RT-PCR system showed that PBL-1 cells were positive for only EBV and negative for more than 160 other viruses including HIV-1 and KSHV (Supplementary Table 1).

### Morphological, immunological, and genetic character of PBL-1

Giemsa staining revealed that PBL-1 had basophilic cytoplasm with a perinuclear halo and an unevenly distributed and enlarged nucleus with marked nucleoli (Fig. 1a). Many large cells had two nuclei. Electron microscopy demonstrated abundant rough endoplasmic reticulum around the nucleus (Fig. 1b). Flow cytometry and immunofluorescence analysis revealed that PBL-1 were positive for CD38, CD138, CD45RA, Blimp-1, MDM2, MyD88, gp80 (IL-6Ra), and gp130 (IL-6Rb) (Supplementary Figure 4). Flow cytometry and immunofluorescence analysis revealed that PBL-1 were positive for CD38, CD138, CD45RA, Blimp-1, MDM2, MyD88, gp80 (IL-6Ra), and gp130 (IL-6Rb) and negative for Kaposi’s sarcoma-associated herpesvirus (KSHV) and HIV-1 (Supplementary Figure 3a).

Chromosomal analysis revealed a complex karyotype — the majority of the cells were diploid with modal 82 chromosomes (Supplementary Figure 4). Southern blotting analysis indicated an IgH gene rearrangement, and BioMed2 analysis revealed an immunoglobulin kappa gene rearrangement, indicating a B cell lineage (Supplementary Figure 4).

Fluorescence in situ hybridization (FISH) with a triple colour-dual fusion probe of IgH and c-myc revealed that PBL-1 had an IgH/c-myc rearrangement (Supplementary Figure 4d), whereas there were no bcl-2 or bcl-6 gene splits (data not shown). PCR and sequence analysis identified a break point in the IgH/c-myc rearrangement that was upstream of exon 1 of c-myc and downstream of the IgH regulatory region (Supplementary Figure 4e and 4f). Immunofluorescence detection of supernatants from the PBL-1 culture medium revealed that PBL-1 secreted no immunoglobulin heavy or light chains (data not shown). Sequence analysis of c-myc, p53, and myx88 revealed these genes had no recurring point mutations in PBL-1 compared with reference sequences (data not shown).

### EBV infection in PBL-1

RT-PCR revealed that PBL-1 was positive for EBER-1 and EBNA-1 mRNA but negative for EBNA-2, latent membrane protein 1 (LMP-1), LMP-2A, and LMP-2B mRNA, indicating that the EBV status in PBL-1 was Latency I (Supplementary Figure 3c). RT-PCR also revealed Qp promoter usage and that the EBV genome of PBL-1 are in the form of a linear or circular episome, and demonstrated its interleukin 6 (IL-6)-dependent growth. In addition, the treatment effect of therapeutic agents was investigated.
beta-actin genome regardless of chemical or immunological stimulation (Supplementary Figure 3d and e). These data suggest an integrated form of the EBV genome in PBL-1.

**PBL-1 is dependent on IL-6 for proliferation and survival.** PBL-1 showed constant growth in medium supplemented with 5 ng/mL of IL-6. The XTT assay showed the IL-6-dose-dependent viability of PBL-1 (EC<sub>50</sub> = 0.237 ng/mL) (Fig. 4a). The XTT assay and cell viability counting indicated that other cytokines including IL-8, IL-4, IL-11, Monocyte Chemotactic Protein-1 (MCP-1), and oncostatin M had no effect on PBL-1 viability (Fig. 4b). Western blot analysis showed that starvation of IL-6 led to PBL-1 apoptosis and the cleavage of caspases-2, -3, -9, and PARP (Fig. 4c). Flow cytometry revealed that annexin V expression was induced at 6 hours after IL-6 starvation in PBL-1 (Fig. 4d), and BrdU assay showed a decrease of DNA synthesis in PBL-1 at 24 hours (Supplementary Figure 5a). IL-6 binds to soluble or membranous IL-6 receptor (or gp80, IL-6Ra), and this IL-6/IL-6Ra complex binds to two molecules of gp130, a ubiquitously expressed membranous protein<sup>25</sup>. The IL-6/IL-6R/gp130 complex induces activation of the Jak/Signal Transducers and Activator of Transcription (STAT) 3 pathway<sup>26–28</sup>. Flow cytometry analysis revealed the expression of gp80 and gp130 in PBL-1 (Supplementary Figure 2). In addition, enzyme-linked immunosorbent assay demonstrated that PBL-1 secreted a high concentration of soluble IL-6Ra (4,482 pg/mL in the supernatant of PBL-1, Fig. 4e). Tocilizumab, an anti-IL-6 receptor antibody, inhibited mitochondrial metabolic activity and DNA synthesis in PBL-1 in a dose-dependent manner (IC<sub>50</sub> = 6.11 μg/mL, Fig. 4f, and Supplementary Figure 5b), and induced apoptosis (Supplementary Figure 5c). Lentiviral transduction of PBL-1 with human IL-6, but not a control-gene or vector-transduced cells, without supplementation of IL-6 induced significant autologous proliferation and survival of the transduced cells (p < 0.01) (Fig. 4g). These data demonstrated a dependency on IL-6 for PBL-1 growth.

**Figure 1.** Morphology of PBL-1. (a) Microscopic view of PBL-1. Giemsa staining of original tumour cells in the ascites of an HIV positive PBL patient (upper panel) and PBL-1 (middle panel), and EBER-1 in situ hybridization on a formalin-fixed paraffin-embedded sample of a PBL-1 cell pellet (lower panel) are shown. Each black bar indicates 10 μm. EBV-positive lymphoma tissues from other unrelated patients also showed positive signals in EBER-1 in situ hybridization (data not shown). (b) Transmission electron microscopy of PBL-1. Chromatin concentrated in the centre and margin of the nucleus, with a wheel-like appearance (upper panel). Abundant rough endoplasmic reticulum is observed in the perinuclear region (lower panel).
IL-6/Jak/STAT3 and PI-3K/Akt/mTOR pathways in PBL-1. The Jak/STAT3 pathway is a major signal pathway downstream of IL-6/IL-6R/gp130. To verify the effect of IL-6 on STAT3 in PBL-1, we performed western blotting in the presence or absence of IL-6. While p-STAT3 was abundant in total cell lysates of PBL-1 in the presence of IL-6 (5 ng/mL), the dephosphorylation of p-STAT3 was induced within 1 h after the starvation of IL-6 (Fig. 5a). Moreover, the expression of total STAT3 decreased gradually after the starvation of IL-6. The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signalling pathway is another major pathway of IL-6 signalling downstream of IL-6R/gp130/Jak. Western blotting also revealed that IL-6 starvation induced the phosphorylation of eukaryotic translation initiation factor 4E (eIF4E) and p70S6K and the dephosphorylation of 4E-BP-1, which are factors downstream of the mTOR pathway (Fig. 5a). Phosphoinositide-dependent protein kinase-1 (PDK1), Akt, and p70S6K were phosphorylated at 1 to 6 hours after IL-6 starvation, but they were dephosphorylated immediately after phosphorylation. To compare the efficiency of drugs that affect the Jak/Stat3 and PI3K/Akt/mTOR pathways with other pathways, we screened compound libraries containing more than 100 inhibitors for various oncogenic pathways. Inhibitors for Jak/STAT and PI3K/Akt/mTOR pathways induced cell death similar to general tyrosine kinase or cyclin dependent kinase inhibitors (Supplementary Table 3). The XTT assay revealed that the mTOR inhibitors, everolimus and rapamycin, also inhibited the mitochondrial metabolic activity of PBL-1 in a dose-dependent manner, and that the IC_{50} of each drug for PBL-1 was 187 pM and 9.74 nM, respectively (Fig. 5b and c). Everolimus was effective at a very low dose compared with the other compounds. These data suggested that the mTOR pathway has a significant effect on the growth of PBL-1.

Therapeutic effects of drugs. In addition to Jak, PI3K, Akt, and mTOR inhibitors, we tested other drugs that have an effect on malignant lymphoma or multiple myeloma in vitro and in vivo including proteasome inhibitors, melphalan, pomalidomide, and histone deacetylase (HDAC) inhibitors. The XTT assay showed that these drugs also inhibited the mitochondrial metabolic activity of PBL-1 in a dose-dependent manner. However, the IC_{50} of these drugs was higher than for the mTOR inhibitors. The combined therapeutic effect of the drugs was assessed using the Chou–Talalay Combination index (CI) method. The combination of bortezomib and tocilizumab (CI = 0.83, Fig. 6b), everolimus and tocilizumab (0.95), and panobinostat and tocilizumab (0.55) exhibited a synergistic effect (CI < 1), whereas antagonistic effects (CI > 1) were observed for three combinations (Supplementary Table 5).

Discussion

The cell origin of PBL is thought to be the plasmablast, which is an activated B-cell in the germinal centre that has undergone somatic hypermutation and class switching recombination. The immunophenotype of plasmablasts is CD38 (+) MUM-1 (+) and CD20 (−), as reflected in PBL. The immunophenotype of PBL is similar to that of multiple myeloma except for those with EBV infection. The established cell line, PBL-1, had an immunophenotype typical of plasmablasts, with morphological features that resembled plasmacytoid tumours. To the best of our knowledge, there have been two previous reports of the establishment and characterization of cell lines from this distinct tumour, and one report of a xenograft model of EBV-negative-PBL. A study of two
EBV-positive cell lines, SPIBL-II and III, established by Friis et al. did not report the immunophenotype or culture method used including IL-6-dependency. The SPIBL-II and III cell lines were established from the pleural effusion of an HIV-positive case of plasmablastic lymphoma. Considering that PBL occurred in the ascites as an effusion lymphoma in our case, such an effusion form of PBL that is very rare might contribute to the establishment of a cell line. Another two PBL cell lines, KY-1 and KY-2, reported by Matsuki et al. were established from an immunocompetent patient without HIV infection, and were CD20 (−), CD138 (+), VS38c (+), EMA (+), but CD38 (−) and EBV (−). IL-6-dependency in the culture medium was not described for these reported cell lines, although IL-6 might be associated with the establishment of these cell lines in a xenograft model. The established PBL cell line in this report was IL-6 dependent. The dependency of cell activation by IL-6 through the gp130/Jak/STAT signalling pathway has been established in multiple myeloma. Starvation of IL-6 in PBL-1 led to the dephosphorylation of p-STAT3 and the phosphorylation of Akt, PDK1, and p70S6K within 1 h; however, p-Akt, p-PDK1, and p-p70S6K were dephosphorylated within 24 h (Fig. 5a). Although the factors upstream of the mTOR pathway were temporarily phosphorylated, they were dephosphorylated within a few hours. This phenomenon might be explained by negative feedback downstream of mTOR. Inhibitors to factors upstream of mTOR did not dephosphorylate p-p70S6K, but rapamycin and everolimus effectively dephosphorylated p-p70S6K. mTOR is considered the bottleneck of the pathway. Tocilizumab is an antibody to soluble and membranous IL-6R, and inhibits IL-6 signal transduction. Tocilizumab inhibited mitochondrial metabolic activity in PBL-1 in a dose-dependent manner, suggesting the inhibition of IL-6 signalling might be an effective treatment for PBL. In vivo, PBL cells require IL-6 secreted from surrounding cells such as macrophages. PBL can also secrete cytokines that act on surrounding cells; indeed, IL-8 expression was observed in the supernatant of PBL-1 (Supplementary Figure 1). Furthermore, an autocrine IL-6 mechanism might be involved in the growth of PBL. In primary effusion lymphoma, which is also considered to be derived from plasmablasts, KSHV-encoded viral IL-6 is secreted from lymphoma cells and induces the proliferation of the tumour by an autocrine mechanism.
dependency of PBL on IL-6 secretion and the PBL morphology suggests PBL are biologically related to primary effusion lymphoma.

EBV infected PBL-1 show Latency I. The integration of EBV in host cells is often observed in tumours and cell lines\(^3\). Generally, integration by a virus occurs randomly at fragile sites in the host genome\(^4\). Although the integration site of EBV has not been identified in PBL-1, Southern blot analysis using an EBV-Bam-L probe (Fig. 3a) and dot-like signals of EBV observed in chromosomes by FISH (Fig. 3b), suggested that EBV did integrate into the host genome of PBL-1. Real-time PCR and droplet digital PCR analysis revealed that chemical and immunological stimulations did not induce the reactivation of EBV in PBL-1. In addition, a miRNA cluster

---

**Figure 4.** IL-6-dependent growth of PBL-1. (a) IL-6 concentration and cell viability by XTT assay. Absorbance of XTT assay correlated with the concentration of IL-6. (b) Comparison with other cytokines. PBL-1 proliferated in medium supplemented with IL-6, but not other cytokines. (c) Western blot analysis of apoptosis-associated proteins. (d) Flow cytometry for Annexin V and propidium iodide (PI) apoptosis assay in PBL-1 cultured in medium without IL-6. Hours after IL-6 withdrawal are shown at the top of each panel. (e) sIL-6Ra levels in culture supernatants. High levels of sIL-6Ra were detected in the supernatant of PBL-1 cells. (f) XTT assay of PBL-1 treated with tocilizumab, an anti-IL-6R monoclonal antibody. Tocilizumab decreased the cell proliferation ratio of PBL-1 in a dose dependent manner. (g) Proliferation of PBL-1 transduced with lentivirus expressing IL-6. Transduction of IL-6 by lentivirus vector, but not vector alone, or IFN-α and IFN-β expressing lentiviruses, induced the autologous proliferation of PBL-1. The error bars in each panel represent the standard deviation of the measurements.
in the BamHI-A Rightward Transcript (BART) region of the EBV genome was completely defective in PBL-1. Thus, miR-BARTs are not essential for maintaining this cell line. B95.8 also has a large deletion in BART DNA; however, no report has described deletion of the whole BART genome in EBV among any cases of lymphoma or EBV strains isolated from various diseases or healthy donors43. miR-BARTs were reported to have anti-apoptotic

Figure 5. IL-6 signal pathway in PBL-1. (a) Western blot analysis of IL-6 signal-associated proteins. (b) Effect of inhibitors for Jak/STAT and PI3K/Akt/mTOR pathways on PBL-1 by XTT assay. Cell proliferation ratio (%) in XTT assay and the concentration of each drug are indicated on the vertical and horizontal axes. All inhibitors were added to medium supplemented with 5 ng/mL IL-6. The error bars represent the standard deviation of the measurements. (c) The IL-6 signal pathway in PBL-1. Inhibitors and the IC₅₀ are indicated at their targets.
or oncogenic functions. A large deletion causing the complete lack of miR-BARTs might be associated with an abortive state. Only EBNA-1 and Qp promoters were expressed in PBL-1, whereas other EBV-encoded genes were not expressed. Recently, it was reported that EBNA-1 enhanced the expression of IL-6R or had linkage with STAT regulation, suggesting it might play a role in the survival of PBL-1.

In this study, bortezomib, pomalidomide, tocilizumab, and mTOR inhibitors (rapamycin, everolimus) were effective at inducing apoptosis in PBL-1. Everolimus, an mTOR inhibitor, is an immunosuppressive drug used for the treatment of breast cancer, neuroendocrine tumours, and kidney cancer; however, there has been no report on the therapeutic use of everolimus for PBL. Inhibitors of the mTOR pathway such as everolimus or rapamycin were more effective on PBL-1 than inhibitors to other factors downstream of IL-6 signalling such as the Jak/Stat pathway. This suggests that mTOR-associated factors play an important role in the IL-6 signalling pathway in PBL-1, and that IL-6 signalling pathways, especially mTOR, are a potential therapeutic target for PBL. Furthermore, in this study, bortezomib, a proteasome inhibitor used for the therapy of multiple myeloma, also exhibited a cytotoxic effect on PBL-1. This finding may indicate that PBL-1 has similar pharmacological responses to multiple myeloma. A combination of HDAC and proteasome inhibitors enhanced apoptosis in some lymphomas, multiple myeloma, EBV-associated tumours and cell lines. These drugs might be potential therapeutic candidates for the treatment of PBL.

Methods

Patient. A 60-year-old Japanese male patient with HIV-1 infection was admitted with fever, weight loss, and ascites. His blood CD4 ( + ) cell counts were 316/μL. Flow cytometry analysis indicated the presence of CD19 ( − ), CD20 ( − ), CD38 ( + ) cells in the ascites. Positron emission transfer imaging revealed a large tumour in the transversus colon, and its biopsied specimen showed the infiltration of tumour cells similar to those in the ascites. Tumour cells were CD19 ( − ), CD20 ( − ), CD79a ( − ), CD38 ( + ), CD138 ( + ), CD30 ( − ), EBV- LMP-1 ( − ), EBV-EBNA-2 ( − ), KSHV-latency-associated nuclear antigen 1 ( − ), CD3 ( − ) CD5 ( − ), CD10 ( − ), BCL6 ( − ), MUM1 ( + ), and >95% Ki67 (MIB-1) ( + ) by immunohistochemistry, and EBER-1 ( + ) by in situ hybridization. These results led to a diagnosis of AIDS-related PBL. Six courses of CHOP chemotherapy induced a remission, but the patient eventually succumbed to the recurrence of disease.

Cell culture. To establish a new cell line, tumour cells were collected from the patient ascites and cultured in RPMI 1640 culture medium supplemented with 10% patient ascites, 10% FBS, 10 ng/mL of insulin (Sigma-Aldrich, St. Louis, MO), and 10 ng/mL of transferrin (Sigma-Aldrich) at 37 °C with 5% CO₂. Supplementation of insulin and transferrin was gradually reduced during passages. Finally, cells were grown in RPMI 1640 with 5 ng/mL of IL-6 (PeproTech, Rocky Hill, NJ) and 10% FBS. Single cell cloning was performed using a limiting dilution method in IL-6 containing medium. For the IL-6 starvation study, cells were centrifuged,
and antagonism, respectively. The Chou–Talalay Combination index (CI) was calculated according to a study by Chou et al. Version 1.0 software (http://www.combosyn.com/) 57. A CI value of >1, =1, or >1 indicates synergy, additivity, and antagonism, respectively.

**Immunofluorescence assay.** Suspended cells were centrifuged onto glass slides via Cytospin (Thermo Fisher Scientific, Waltham, MA) to form a single layer of $5 \times 10^4$ cells per spot. The samples were incubated with mouse monoclonal antibodies to CD20, CD38, CD138, and LMP-1 of EBV (Dako, Copenhagen, Denmark) diluted 1:100 with Block Ace (DS Pharma Biomedical, Osaka, Japan) for 1 h at room temperature, followed by Alexa Fluor 488-conjugated goat anti-mouse IgG (H+L) (Molecular Probes, Eugene, OR) diluted 1:500 with PBS for 1 h at room temperature. Nuclear staining was performed with 1 μg/mL 4′,6-diamidino-2-phenylindole. Images were captured with a fluorescence microscope (Olympus, Tokyo, Japan).

**Electron microscopy.** PBL-1 cells were pelleted by centrifugation, fixed with 2.5% glutaraldehyde and 2% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) for 2 h at room temperature, post-fixed in 1% osmium tetroxide, and embedded in Epon. Ultrathin sections were stained with uranyl acetate and lead citrate, and observed under a transmission electron microscope (HT7700, Hitachi High Technologies, Tokyo, Japan) at 80 kV.

**Western blot analysis.** Protein extraction and immunoblotting were performed as described previously56. Briefly, $1 \times 10^6$ cells were lysed in 100 μL of M-PER lysis buffer containing Halt protease and phosphatase inhibitor cocktail (Pierce Biotechnology, Rockford, IL). Cell lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene fluoride microporous membrane (Immobilon-P Transfer Membrane, Millipore, Bedford, MA) using the NuPAGE system (Life Technologies, Carlsbad, CA). The membranes were blocked with Block Ace and probed with primary antibodies followed by horse radish peroxidase-conjugated anti-mouse or anti-rabbit antibodies (Promega, Madison, WI) with an immunoreaction enhancer solution (Can Get Signal, Toyobo, Osaka, Japan). Blots were visualized by Super-Signal West Femto Chemiluminescent Substrate (Thermo Fisher Scientific) and images were captured with a C-Digit Blot Scanner (LI-COR Biosciences, Lincoln, NE).

**Anti-IL6R antibody and drug screening.** Anti-IL6R antibody, tocilizumab (Actemra), was purchased from Chugai Pharmaceutical, Tokyo, Japan, and used at 48 ng–100 μg/mL. To identify drugs that inhibited PBL-1 cell proliferation, PBL-1 cells were cultured in RPMI 1640 with 10% FBS and drugs from the InhibitorSelect 96-well Protein Kinase Inhibitor Library I, II, III (Calbiochem, San Diego, CA) in a 96-well plate at two final concentrations (10 nM and 1 μM). We also added 7 HDAC inhibitors (HDAC inhibitor Set II: Sigma Aldrich) and other antitumour drugs to PBL-1 cells with 5 μg/mL of IL-6 and cultured them for 48 h.

**Analysis for synergism and antagonism of drugs.** PBL-1 cells were cultured in RPMI 1640 with 10% FBS, 5 nM of IL-6 and two drugs (bortezomib, everolimus, tocilizumab and panobinostat) each added as a 2-fold dilution series from 6.4 μg/mL (tocilizumab), 32 nM (bortezomib and panobinostat) or 1.6 nM (everolimus) to determine the IC$_{50}$. XTT assay was performed after 48 hr of culture. A constant combination ratio experiment for the 8 point assay was carried out, as the ratio of (IC$_{50}$ of drug 1)/(IC$_{50}$ of drug 2) was constant. The Chou–Talay Combination index (CI) was calculated according to a study by Chou et al. using CompuSyn Version 1.0 software (http://www.combosyn.com/) 57. A CI value of <1, =1, or >1 indicates synergy, additivity, and antagonism, respectively.

**Statistical analysis.** All results were expressed as the mean ± SD of data obtained in triplicate, from at least three individual experiments. All statistical analyses were performed with Excel software (Microsoft, Bellevue, WA), and GraphPad Prism Version 6.0 software (GraphPad Software, La Jolla, CA). P values < 0.05 were considered statistically significant.

**Ethical statement.** The study protocol was approved by the Institutional Review Board, National Institute of Infectious Diseases (Approval No. 512) and Tokyo Metropolitan Komagome Hospital (Approval No. 1552). Informed consent was obtained from the patient with PBL. All methods were performed in accordance with the relevant guidelines and regulations.

Further methods are provided in the supplemental Materials and Methods.

**Data availability.** The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
References

1. Castillo, J. J., Bibas, M. & Miranda, R. N. The biology and treatment of plasmablastic lymphoma. Blood 125, 2323–2330 (2015).
2. Stein, H. H. N. & Campo, E. In WHO Classification of Tumors of the Haematopoietic and Lymphoid Tissues, 256–257 (IARC, 2008).
3. Ota, Y. et al. Classification of AIDS-related lymphoma cases between 1987 and 2012 in Japan based on the WHO classification of lymphomas, fourth edition. Cancer Med 3, 143–153 (2014).
4. Carbone, A. AIDS-related non-Hodgkin’s lymphomas: from pathology and molecular pathogenesis to treatment. Hum Pathol 33, 392–404 (2002).
5. Morcillo, J. et al. Clinicopathological comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol 38, 875–886 (2014).
6. Castillo, J., Pantanowitz, L. & Dezube, B. J. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol 83, 804–809 (2008).
7. Swerdlov, S. H., C. E. & Harris, N. L. In WHO Classification of tumours of haematopoietic and lymphoid tissues (IARC, 2008).
8. Luo, W. J. et al. Epstein-Barr virus is integrated between REL and BCL-11A in American Burkitt lymphoma cell line (NAB-2). Lab Invest 84, 1193–1199 (2004).
9. Takakawa, T., Luo, W. J., Ham, M. F., Wada, N. & Aozasa, K. Identification of Epstein-Barr virus integrated sites in lymphoblastoid cell line (IB4). Virus Res 108, 133–138 (2005).
10. Gao, J., Luo, X., Tang, K., Li, X. & Li, G. Epstein-Barr virus integrates frequently into chromosome 4q, 2q, 1q and 7q of Burkitt’s lymphoma cell line (Raji). J Virol Methods 136, 193–199 (2006).
11. Lestou, V. S. et al. Non-random integration of Epstein-Barr virus in lymphoblastoid cell lines. Genes Chromosomes Cancer 8, 38–48 (1993).
12. Hurley, E. A. et al. When Epstein-Barr virus persistently infects B-cell lines, it frequently integrates. J Virol 65, 1245–1254 (1991).
13. Popescu, N. C., Chen, M. C., Simpson, S., Solinas, S. & DiPaolo, J. A. Burkitt lymphoma cell line with integrated Epstein-Barr virus at a stable chromosome modification site. Virology 195, 248–253 (1993).
14. Al-Malki, M. M., Castillo, J. J., Sloan, J. M. & Re, A. Hematopoietic cell transplantation for plasmablastic lymphoma: a review. Biol Blood Marrow Transplant 20, 1877–1884 (2014).
15. Barta, S. K. et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood 122, 3251–3262 (2013).
16. Bibas, M. & Castillo, J. J. Current knowledge on HIV-associated Plasmablastic Lymphoma. Mediterr J Hematol Infect Dis 6, 2014064 (2014).
17. Loghavi, S. et al. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathological analysis of 61 patients. J Hemat Oncol 8, 65 (2015).
18. Zelenetz, A. D. et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin’s lymphomas. J Natl Compr Canc Netw 8, 288–334 (2010).
19. Castillo, J. J., Reigan, J. L., Sikov, W. M. & Winer, E. S. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol 169, 352–355 (2015).
20. Fernandez-Alvarez, R. et al. Bortezomib plus CHOP for the treatment of HIV-associated plasmablastic lymphoma: clinical experience in three patients. Leuk Lymphoma 1–4 (2015).
21. Elhamamy, G., Al Mussaed, E. & Alzahrani, A. M. Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions. Adv Hematol 2015, 315289 (2015).
22. Hiroswa, M., Morimoto, H., Shibuya, R., Shimajiri, S. & Tsukada, J. A striking response of plasmablastic lymphoma of the oral cavity to bortezomib: a case report. Biomark Res 3, 28 (2015).
23. Cencini, E. et al. Long-term remission in a case of plasmablastic lymphoma treated with COMP (cyclophosphamide, liposomal doxorubicin, vincristine, prednisone) and bortezomib. Eur J Haematol 96, 650–654 (2016).
24. Fedele, P. L. et al. Infusional dose-adjusted etoposide plus bortezomib for the treatment of plasmablastic lymphoma. Ann Hematol 95, 667–668 (2016).
25. Jones, S. A., Scheller, J. & Rose-John, S. Therapeutic strategies for the blockade of IL-6/gp130 signaling. J Clin Invest 121, 3375–3383 (2011).
26. Dechow, T. et al. GIP130 activation induces myeloma and collaborates with MYC. J Clin Invest 124, 5263–5274 (2014).
27. Taga, T. & Kishimoto, T. Signaling mechanisms through cytokine receptors that share signal transducing receptor components. Curr Opin Immunol 7, 17–23 (1995).
28. Mihaara, M. et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 5, 1731–1740 (2005).
29. Shi, Y., Hsu, J. H., Hu, L., Gera, J. & Lichtenstein, A. Signal pathways involved in GP130 activation of p70S6K, and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6. J Biol Chem 277, 15712–15720 (2002).
30. Rape, N. et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 104, 4188–4193 (2004).
31. Dolcetti, R., Gloghini, A., Caruso, A. & Carbone, A. A lymphomagenic role for HIV beyond immune suppression? Blood 127, 1403–1409 (2016).
32. Vega, F. et al. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol 18, 806–815 (2005).
33. Friis, A. et al. Epstein Barr virus DNA analysis in blood predicts disease progression in a rare case of plasmablastic lymphoma with effusion. Infect Agent Cancer 8, 28 (2013).
34. Matsuki, E. et al. Identification of loss of p16 expression and upregulation of MDR-1 as genetic events resulting from two novel chromosomal translocations found in a plasmablastic lymphoma of the uterus. Clin Cancer Res 17, 2101–2109 (2011).
35. Chapuy, B. et al. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. Blood 127, 2203–2213 (2016).
36. Manning, B. D. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 167, 399–403 (2004).
37. Jefferies, H. B. et al. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70S6K. EMBO J 16, 3663–3704 (1997).
38. Guo, H. et al. Everolimus exhibits anti-tumorigenic activity in obesity-induced ovarian cancer. Oncotarget 7, 20338–20356 (2016).
39. Meads, M. B. & Medvecky, P. G. Kaposi’s sarcoma-associated herpesvirus-encoded viral interleukin-6 is secreted and modified differently than human interleukin-6: evidence for a unique autocrine signaling mechanism. J Biol Chem 277, 51793–51803 (2004).
40. Rosean, T. R. et al. KSHV-encoded vIL-6 collaborates with deregulated c-Myc to drive plasmablastic neoplasms in mice. Blood 126, e398 (2015).
41. Osborne, J., Moore, P. S. & Chang, Y. KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways. Hum Immunol 60, 921–927 (1999).
42. Reisinger, J., Rumpler, S., Lion, T. & Ambros, P. Visualization of episomal and integrated Epstein-Barr virus DNA by fiber fluorescence in situ hybridization. Int J Cancer 118, 1603–1608 (2006).
43. Palser, A. L. et al. Genome diversity of Epstein-Barr virus from multiple tumor types and normal infection. J Virol 89, 5222–5237 (2015).
44. Kang, D., Skalsky, R. L. & Cullen, B. R. EBV BART MicroRNAs Target Multiple Pro-apoptotic Cellular Genes to Promote Epithelial Cell Survival. PLoS Pathog 11, e1004975 (2015).
45. Ross, N., Gandhi, M. K. & Nourse, J. P. The Epstein-Barr virus microRNA BART11-5p targets the early B-cell transcription factor EBF1. *Am J Blood Res* 3, 210–224 (2013).
46. Tempera, I. *et al.* Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival. *J Virol* 90, 345–355 (2015).
47. Lu, F. *et al.* Genome-wide analysis of host-chromosome binding sites for Epstein-Barr Virus Nuclear Antigen 1 (EBNA1). *Viril J* 7, 262 (2010).

48. Chen, H. *et al.* Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors. *J Virol* 75, 2929–2937 (2001).
49. Hui, K. F., Leung, Y. Y., Yeung, P. L., Middeldorp, J. M. & Chiang, A. K. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines. *Br J Haematol* 167, 639–650 (2014).
50. Bhatt, S. *et al.* Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma. *J Clin Invest* 123, 2616–2628 (2013).

51. Hui, K. F., Lam, B. H., Ho, D. N., Tsao, S. W. & Chiang, A. K. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus. *Mol Cancer Ther* 12, 747–758 (2013).
52. Dimopoulos, M. *et al.* Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. *Lancet Oncol* 14, 1129–1140 (2013).
53. Dasmahapatra, G. *et al.* The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. *Blood* 115, 4478–4487 (2010).

54. Iwasaki, Y. *et al.* Establishment and characterization of a human Epstein-Barr virus-associated gastric carcinoma in SCID mice. *J Virol* 72, 8321–8326 (1998).
55. Cortes-Dericks, L., Froment, L., Kocher, G. & Schmid, R. A. Human lung-derived mesenchymal stem cell-conditioned medium exerts in vitro antitumor effects in malignant pleural mesothelioma cell lines. *Stem Cell Res Ther* 7, 25 (2016).
56. Kanno, T. *et al.* Fumagillin, a potent angiogenesis inhibitor, induces Kaposi sarcoma-associated herpesvirus replication in primary effusion lymphoma cells. *Biochem Biophys Res Commun* 463, 1267–1272 (2015).

57. Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. *Pharmacol Rev* 58, 621–681 (2006).

Acknowledgements
We are grateful to Hiroyuki Miyoshi (Riken BioResource Center, Keio University) and Atsushi Miyawaki (Riken Brain Science Institute) for providing the lentivirus plasmids. This work was financially supported by the Research Program on HIV/AIDS (grant numbers 15K0108011h0101, 15K0108011h0003, 16K0410209j0102, 16K0410108j0101, and 16K041010j0001) and the Research Program on Emerging and Re-emerging Infectious Diseases (grant numbers 15K0108011h0503 and 16K0108119j0001) from the Japan Agency for Medical Research and Development; and Grants-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science (grant number 15K08509).

Author Contributions
S.M. performed and analysed the experiments and wrote the manuscript. H.K. designed the study, performed and analysed the experiments, and critically revised the drafting of the manuscript. T.H. and A.S. collected clinical samples and provided clinical information. H.F., Y.S., M.Ka. and T.Su. performed pathological experiments. T.Se. and M.Ku. performed next generation sequencing for miRNA. H.H. and M.F. analysed the pathological data. All authors have read and approved the final manuscript.

Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-10684-5

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2017